Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with staphylococcus aureus bacteremia and mild to moderate renal impairment

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1192-1200

  Moise, Pamela A ^a   Amodio Groton, Maria ^a   Rashid, Mohamad ^b   Lamp, Kenneth C ^a   Hoffman Roberts, Holly L ^a   Sakoulas, George ^c   Yoon, Min J ^a   Schweitzer, Suzanne ^b   Rastogi, Anjay ^b  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CREATINE KINASE; DAPTOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE INFECTION; DRUG EFFICACY; ENDOCARDITIS; FEMALE; HUMAN; INFECTIOUS ARTHRITIS; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STAPHYLOCOCCAL BACTEREMIA;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMS; CREATINE KINASE; DAPTOMYCIN; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; MALE; REGISTRIES; RENAL INSUFFICIENCY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 84874090811     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02192-12     Document Type: Article

References (40)

1. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Active Bacterial Core Surveillance (ABCs) MRSA Investigators. 2007. Invasive methicillin- resistant Staphylococcus aureus infection in the United States. JAMA 298:1763-1771.
2. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gobell IB. 2012. Predictors of mortality in Staphylococcus aureus bacteremia. Clin. Microbiol. Rev. 25:362-386.
3. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak M, Talan DA, Chambers HF, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55. (Erratum, 53:319.).
4. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98. (Erratum, 66:887.).
5. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398 -2402.
6. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcusaureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138- 2144.
7. Horey A, Mergenhagen KA, Mattappallil A. 2012 Oct 16. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Ann. Pharmacother. doi:10 .1345/aph.1R158.
8. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD. 2011. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob. Agents Chemother. 55:5475-5479.
9. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. 2010. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am. J. Med. 123:1143-1149.
10. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. 2011. Vancomycin: we can't get there from here. Clin. Infect. Dis. 52:969- 974.
11. Wong-Beringer A, Joo J, Tse E, Beringer P. 2011. Vancomycinassociated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int. J. Antimicrob. Agents 37:95-101.
12. Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. 2007. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcome. Arch. Intern. Med. 167:1861-1867.
13. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38:1700 -1705.
14. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
15. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. 2012. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin. Infect. Dis. 54:51-58.
16. Cubist Pharmaceuticals. November 2010. Cubicin (daptomycin for injection) current prescribing information. Cubist Pharmaceuticals, Lexington, MA.
17. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE, Saureus Endocarditis and Bacteremia Study Group. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355: 653-665.
18. Rand KA, Houck HJ. 2004. Synergy of daptomycin with oxacillin and other lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48:2871-2875.
19. Miller HH, Nolan L, Moise P. 2012. Novel therapeutic combinations for methicillin-resistant Staphylococcus aureus bacteremia and prosthetic joint infection with evolving multidrug resistance. Infect. Dis. Clin. Pract. 20:157-160.
20. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillinresistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin. Infect. Dis. 53:158 -163.
21. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. 2012. Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob. Agents Chemother. 56:6192- 6200.
22. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. 2013. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 57:66-73.
23. Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, Shukla SK. 2012. Addition of ceftaroline to daptomycin after the emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob. Agents Chemother. 56:5296- 5302.
24. Rolston KV, Segreti J, Lamp KC, Friedrich LV. 2007. Cubicin Outcomes Registry and Experience (CORE) methodology. Am. J. Med. 120:S4 -S5.
25. Couture M, Simard M, Gourde P, Lessard C, Gurmani K, Lim L, Carrier D, Bergeron MG, Beauchamp D. 1994. Daptomycin may attenuate experimental tobramycin nephrotoxicity by electrostatic complexation to tobramycin. Antimicrob. Agents Chemother. 38:742-749.
26. Gurnani K, Khouri H, Couture M, Bergeron MG, Beauchamp D, Carrier D. 1995. Molecular basis of the inhibition of gentamicin nephrotoxicity by daptomycin; an infrared spectroscopic investigation. Biochim. Biophys. Acta 1237:86 -94.
27. Carrier D, Bou Khalil M, Kealey A. 1998. Modulation of phospholipase A2 activity by aminoglycosides and daptomycin: a Fourier transform infrared spectroscopic study. Biochemistry 37:7589 -7597.
28. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, Daptomycin 98-01 and 99-01 Investigators. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38:1673-1681.
29. Kullar R, McClellan I, Geriak M, Sakoulas G. 2012. Efficacy and safety of daptomycin in the treatment of Gram-positive infections in patients with renal impairment, abstr. K-1631. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother.
30. Moise PA, North D, Steenbergen JN, Sakoulas G. 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 9:617- 624.
31. Fowler VG Jr, Sakoulas G, McIntyre LM, Meka VG, Arbeit RD, Cabell CH, Stryjewski ME, Eliopoulos GM, Reller LB, Corey GR, Jones T, Lucindo N, Yeaman MR, Bayer AS. 2004. Persistent bacteremia in methicillin-resistant Staphylococcus aureus bloodstream infections is associated with agr dysfunction and low-level resistance to thrombin-induced platelet microbicidal protein. J. Infect. Dis. 190:1140 -1149.
32. Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. 2012. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin- naïve bacteremia patients. J. Infect. Dis. 206:1160 -1167.
33. Rajendran PM, Young D, Maurer T, Chambers H, Perdreau- Remington F, Ro P, Harris H. 2007. Randomized, double-blind, placebo- controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillinresistant Staphylococcus aureus infection. Antimicrob. Agents Chemother. 51:4044-4048.
34. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. 2007. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 195:202-211.
35. Bayer AS, Ramos MD, Menzies BE, Yeaman MR. 1997. Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect. Immun. 65:4652- 4660.
36. Savolainen K, Paulin L, Westerlund-Wikstrom B, Foster TJ, Korhonen TK, Kuusela P. 2001. Expression of pls, a gene closely associated with the mecA gene of methicillin-resistant Staphylococcus aureus, prevents bacterial adhesion in vitro. Infect. Immun. 69:3013-3020.
37. Ahmed S, Meghji S, Williams RJ, Henderson B, Brock JH, Nair SP. 2001. Staphylococcus aureus fibronectin binding proteins are essential for internalization by osteoblasts but do not account for differences in intracellular levels of bacteria. Infect. Immun. 69:2872-2877.
38. Cunningham R, Cockayne A, Humphreys H. 1996. Clinical and molecular aspects of the pathogenesis of Staphylococcus aureus bone and joint infection. J. Med. Microbiol. 44:157-164.
39. Rennermalm A, Li YH, Jarstrand C, Brauner A, Brennan FR, Flock JI. 2001. Antibodies against a truncated Staphylococcus aureus fibronectinbinding protein protect against dissemination of infection in the rat. Vaccine 19:3376 -3383.
40. Peacock SJ, Day NP, Thomas MG, Berendt AR, Foster TJ. 2000. Clinical isolates of Staphylococcus aureus exhibit diversity in fnb genes and adhesion to human fibronectin. J. Infect. 41:23-31.